Akebia Therapeutics, Inc. (AKBA) vs InflaRx N.V. (IFRX)
A side-by-side comparison of Akebia Therapeutics, Inc. and InflaRx N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKBA
Akebia Therapeutics, Inc.
$0.90HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
IFRX
InflaRx N.V.
$1.63HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT
Total return — AKBA vs IFRX
growth of $100 · dividends reinvested · last 9yAKBA -94.9% (-28.1%/yr)IFRX -88.8% (-21.6%/yr)IFRX compounded faster over this window
AKBA IFRX
AKBA vs IFRX: by the numbers
- •AKBA is the larger company ($240M vs $239M market cap).
- •Both run net losses; AKBA's is the smaller (-13.54% vs -155582.08% net margin).
Metrics side by side
Valuation
| Metric | AKBA | IFRX |
|---|---|---|
| P/S ratio | 1.10 | N/A |
| P/B ratio | 9.60 | 1.43 |
| FCF yield | 16.73% | N/A |
Profitability
| Metric | AKBA | IFRX |
|---|---|---|
| Gross margin | 79.48% | -24677.94% |
| Operating margin | 9.95% | -164525.50% |
| Net margin | -13.54% | -155582.08% |
| ROE | -118.58% | -27.27% |
| ROIC | -7.08% | -25.38% |
Growth (annualized)
| Metric | AKBA | IFRX |
|---|---|---|
| Revenue CAGR (5Y) | -0.26% | N/A |
| Total return CAGR (5Y) | -20.07% | -7.34% |
Frequently asked
- How have AKBA and IFRX total returns compared?
- Over the past 5 years, AKBA delivered -20.07% and IFRX delivered -7.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Akebia Therapeutics ROEInflaRx ROEAkebia Therapeutics operating marginInflaRx operating marginAkebia Therapeutics revenue growthInflaRx revenue growthAkebia Therapeutics free cash flowInflaRx free cash flow
Akebia Therapeutics & InflaRx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.